NVO - Novo Nordisk - ADR
Close
139.16
1.640 1.178%
Share volume: 2,714,411
Last Updated: Fri 30 Aug 2024 10:00:02 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$137.52
1.64
1.19%
Fundamental analysis
48%
Profitability
64%
Dept financing
16%
Liquidity
52%
Performance
40%
Performance
5 Days
1.60%
1 Month
8.09%
3 Months
5.18%
6 Months
15.75%
1 Year
49.61%
2 Year
168.76%
Key data
Stock price
$139.16
DAY RANGE
$137.85 - $139.74
52 WEEK RANGE
$86.02 - $147.60
52 WEEK CHANGE
$0.49
DIVIDEND
$0.5126
EX-DIVIDEND DATE
08/16/2024
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Lars Fruergaard Joergensen
Region: US
Website: https://www.novonordisk.com/
Employees: 57,089
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.novonordisk.com/
Employees: 57,089
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
Recent news